“Buzz on the Street” Show: Todos Medical (OTCQB: TOMDF) Branding and Distribution Agreement

Christel Deskins

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States.” Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for […]

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States.”

Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an exclusive branding and distribution agreement with Australia-headquartered Melbourne Biotech, a US FDA-registered manufacturer, to supply high complexity CLIA laboratories in the United States with 96 and 384 well Real Time Polymerase Chain Reaction (RT-PCR) machines. Melbourne RT-PCR machines come with 4, 5 or 6 channels to be able to identify multiple genes in the same well. Todos intends to focus the initial deployment of these RT-PCR machines towards its ongoing mobile high complexity CLIA lab project that it expects to reach the commercialization stage early in the fourth quarter of 2020.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

For more information, please visit: Todos Medical Ltd

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Next Post

Vontobel Asset Management Wins Global Equity Strategy of the Year

NEW YORK, Sept. 30, 2020 /PRNewswire/ — “On behalf of my fellow portfolio managers and analysts, it is an honor to accept this award in recognition of our time-tested and disciplined investment process,” said Matthew Benkendorf, Chief Investment Officer, Quality Growth Boutique. “With every decision we make, we put ourselves […]